Alliances
Denali Therapeutics, located in South San Francisco, California, had a lot of news to share today.
Ionis Pharmaceuticals has signed a worldwide license deal to Akcea Therapeutics for inotersen and AKCEA-TTR-LRx in a deal that could hit $1.7 billion.
Immutep Limited announced it will pair its lead immunotherapy product with Merck’s blockbuster PD-1 inhibitor Keytruda to treat three solid tumor types in a single trial.
Sanofi SA and Evotec AG have teamed up to form an infectious disease research and development program.
This week Pfizer notified the Bay Area-based company of its intent to terminate its five-year-old oncology collaboration.
Merck and Tokyo-based Eisai Co. have signed a strategic collaboration deal to develop and commercialize Lenvima with Merck’s anti-PD-1 drug Keytruda.
Ligand Pharmaceuticals is licensing LGD-6972, a glucagon receptor antagonist (GRA), to Roivant Sciences for $20 million.
Magenta Therapeutics is teaming up with Ladenburg, Germany-based Heidelberg Pharma to improve curative bone marrow transplantation.
Celgene handed over $101 million in upfront monies to San Diego-based Vividion Therapeutics, Inc. as part of an agreement to develop small molecule therapies.
Novartis inked a collaboration deal with Pear Therapeutics to develop prescription digital therapeutics for schizophrenia and multiple sclerosis (MS).
PRESS RELEASES